Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 40

1.

Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substrate.

Krumova P, Reyniers L, Meyer M, Lobbestael E, Stauffer D, Gerrits B, Muller L, Hoving S, Kaupmann K, Voshol J, Fabbro D, Bauer A, Rovelli G, Taymans JM, Bouwmeester T, Baekelandt V.

FASEB J. 2015 Apr 8. pii: fj.14-262329. [Epub ahead of print]

PMID:
25854701
2.

Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism.

Taymans JM, Baekelandt V.

Front Genet. 2014 Nov 7;5:382. doi: 10.3389/fgene.2014.00382. eCollection 2014. Review.

3.

Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.

Göring S, Taymans JM, Baekelandt V, Schmidt B.

Bioorg Med Chem Lett. 2014 Oct 1;24(19):4630-7. doi: 10.1016/j.bmcl.2014.08.049. Epub 2014 Aug 29.

PMID:
25219901
4.

Regulation and targeting of enzymes mediating Parkinson's disease pathogenesis: focus on Parkinson's disease kinases, GTPases, and ATPases.

Taymans JM, Baekelandt V, Harvey K.

Front Mol Neurosci. 2014 Jul 29;7:71. doi: 10.3389/fnmol.2014.00071. eCollection 2014. No abstract available.

5.

Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways.

Reyniers L, Del Giudice MG, Civiero L, Belluzzi E, Lobbestael E, Beilina A, Arrigoni G, Derua R, Waelkens E, Li Y, Crosio C, Iaccarino C, Cookson MR, Baekelandt V, Greggio E, Taymans JM.

J Neurochem. 2014 Jun 20. doi: 10.1111/jnc.12798. [Epub ahead of print]

PMID:
24947832
6.

In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.

Vancraenenbroeck R, De Raeymaecker J, Lobbestael E, Gao F, De Maeyer M, Voet A, Baekelandt V, Taymans JM.

Front Mol Neurosci. 2014 Jun 3;7:51. doi: 10.3389/fnmol.2014.00051. eCollection 2014.

7.
8.

Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.

Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA; International Parkinson’s Disease Genomics Consortium; North American Brain Expression Consortium, Olszewski M, Hauser DN, Kumaran R, Lozano AM, Baekelandt V, Greene LE, Taymans JM, Greggio E, Cookson MR.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2626-31. doi: 10.1073/pnas.1318306111. Epub 2014 Feb 7.

9.

In vitro phosphorylation does not influence the aggregation kinetics of WT α-synuclein in contrast to its phosphorylation mutants.

Schreurs S, Gerard M, Derua R, Waelkens E, Taymans JM, Baekelandt V, Engelborghs Y.

Int J Mol Sci. 2014 Jan 15;15(1):1040-67. doi: 10.3390/ijms15011040.

10.

A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation.

Law BM, Spain VA, Leinster VH, Chia R, Beilina A, Cho HJ, Taymans JM, Urban MK, Sancho RM, Blanca Ramírez M, Biskup S, Baekelandt V, Cai H, Cookson MR, Berwick DC, Harvey K.

J Biol Chem. 2014 Jan 10;289(2):895-908. doi: 10.1074/jbc.M113.507913. Epub 2013 Nov 25.

11.

Metabolic labeling of leucine rich repeat kinases 1 and 2 with radioactive phosphate.

Taymans JM, Gao F, Baekelandt V.

J Vis Exp. 2013 Sep 18;(79):e50523. doi: 10.3791/50523.

PMID:
24084685
12.

Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.

Lobbestael E, Zhao J, Rudenko IN, Beylina A, Gao F, Wetter J, Beullens M, Bollen M, Cookson MR, Baekelandt V, Nichols RJ, Taymans JM.

Biochem J. 2013 Nov 15;456(1):119-28. doi: 10.1042/BJ20121772.

13.

MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.

Cho HJ, Liu G, Jin SM, Parisiadou L, Xie C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, Lobbestael E, Baekelandt V, Taymans JM, He P, Troncoso JC, Shen Y, Cai H.

Hum Mol Genet. 2013 Feb 1;22(3):608-20. doi: 10.1093/hmg/dds470. Epub 2012 Nov 2.

14.

Phosphorylation of LRRK2: from kinase to substrate.

Lobbestael E, Baekelandt V, Taymans JM.

Biochem Soc Trans. 2012 Oct;40(5):1102-10. Review.

PMID:
22988873
15.

The GTPase function of LRRK2.

Taymans JM.

Biochem Soc Trans. 2012 Oct;40(5):1063-9. Review.

PMID:
22988866
16.

Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers.

Civiero L, Vancraenenbroeck R, Belluzzi E, Beilina A, Lobbestael E, Reyniers L, Gao F, Micetic I, De Maeyer M, Bubacco L, Baekelandt V, Cookson MR, Greggio E, Taymans JM.

PLoS One. 2012;7(8):e43472. doi: 10.1371/journal.pone.0043472. Epub 2012 Aug 29.

17.

Introduction to the journal of learning disabilities special issue: adults with learning disabilities in adult education.

Taymans JM, Kosaraju S.

J Learn Disabil. 2012 Jan-Feb;45(1):3-4. doi: 10.1177/0022219411426860. No abstract available.

PMID:
22267406
18.

Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.

Vancraenenbroeck R, Lobbestael E, Weeks SD, Strelkov SV, Baekelandt V, Taymans JM, De Maeyer M.

Biochim Biophys Acta. 2012 Mar;1824(3):450-60. doi: 10.1016/j.bbapap.2011.12.009. Epub 2012 Jan 11.

PMID:
22251894
19.

Legal and definitional issues affecting the identification and education of adults with specific learning disabilities in adult education programs.

Taymans JM.

J Learn Disabil. 2012 Jan-Feb;45(1):5-16. doi: 10.1177/0022219411426857. Epub 2011 Dec 1.

PMID:
22134963
20.

LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding.

Taymans JM, Vancraenenbroeck R, Ollikainen P, Beilina A, Lobbestael E, De Maeyer M, Baekelandt V, Cookson MR.

PLoS One. 2011;6(8):e23207. doi: 10.1371/journal.pone.0023207. Epub 2011 Aug 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk